𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Nitric oxide in patients with transitional bladder cancer

✍ Scribed by Ana María Eiján; Inés Piccardo; María Doris Riveros; Eduardo Omar Sandes; Hugo Porcella; María Adela Jasnis; Eugenia Sacerdote De Lustig; Hector Malagrino; Leonardo Pasik; Alberto Ricardo Casabé

Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
100 KB
Volume
81
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pronounced microsatellite instability in
Pronounced microsatellite instability in transitional cell carcinomas from young patients with bladder cancer
✍ Mariann Christensen; Maria A. Jensen; Hans Wolf; Torben F. Ørntoft 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 126 KB 👁 2 views

Microsatellites may show loss of heterozygosity as well as instability of the repeats. We examined 22 different microsatellites in 14 bladder tumours (7 grade II non-invasive, 7 grade III/IV invasive) and found altered CA repeat length compared with leukocytes, indicating instability, in several mic

Metachronous bladder tumors in patients
Metachronous bladder tumors in patients with upper urinary tract transitional cell carcinoma
✍ Eliahu Mukamel; Dan Simon; Ciro Servadio; Myriam Konichezky; Herzlia Hadar; Abra 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 326 KB 👁 1 views

Sixty-nine patients who underwent nephroureterectomy for upper urinary tract transitional cell carcinoma were included in the study. The following data were collected for each patient: grade and stage of renalhreteral tumor, tumor location, timing of tumor appearance and recurrence in the bladder, g

Adjuvant Bestatin immunotherapy in patie
Adjuvant Bestatin immunotherapy in patients with transitional cell carcinoma of the bladder
✍ Henric Blomgren; Ingemar Näslund; Pier-Luigi Esposti; Lise Johansen; Ove Aaskove 📂 Article 📅 1987 🏛 Springer-Verlag 🌐 English ⚖ 554 KB

The first clinical results of an ongoing, prospective trial to determine the value of adjuvant Bestatin immunotherapy in the management of bladder cancer are presented. Patients with nonmetastatic transitional cell carcinoma of the bladder, scheduled for full dose local radiation therapy (64 Gy), we